Breast Cancer

Key

- Open for Enrollment
- In Development
- Enrollment on Hold

Pre-Op Therapy

- No Trial Currently Available

Surgical Therapy

- IRB#9340 Phase II breast conservation surgery and radiation therapy study

Adjuvant Therapy

- No Trial Currently Available

1st line MBC Therapy

- IRB # 16390 A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients with Advanced Breast Cancer
- IRB # 9076 Phase III study in postmenopausal women that have progressed on or after mTOR therapy

2nd line MBC Therapy

3rd line MBC Therapy

- No Trial Currently Available

“Heavily Pretreated” Therapy

- No Trial Currently Available

Endocrine Therapy

ER/PR-POSITIVE HER2 NEGATIVE

- IRB#6256 ISPY2 Investigation of Serial Studies to Predict your Therapeutic response with imaging/molecular

HER2 POSITIVE

- IRB#6256 ISPY2 Investigation of Serial Studies to Predict your Therapeutic response with imaging/molecular

“TRIPLE NEGATIVE” ER/PR –NEGATIVE HER2-NEGATIVE

- IRB#6256 ISPY2 Investigation of Serial Studies to Predict your Therapeutic response with imaging/molecular

IRB#6256 ISPY2 Investigation of Serial Studies to Predict your Therapeutic response with imaging/molecular

IRB#15366 Phase 2 Study of ONT-380 vs. Placebo with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (Applies to Adjuvant, 1st line and beyond HER2 + MBC therapy)

IRB # 11351 Phase 3 Trial of Standard Chemotherapy With or Without a PARP Inhibitor in Metastatic or Locally Advanced Unresectable Breast Cancer

IRB #15176 A Randomized Open-Label Phase 3 Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician’s Choice for Metastatic Triple Negative Breast Cancer (mTNBC)

2/14/2017

www.ohsu.edu/cancer